Search - tctmd.com

Displaying 201 - 220 of 332

Sort: Relevancy | Date

Potential Warning Signs Seen for NOAC Use After TAVR

News Daily News

Potential Warning Signs Seen for NOAC Use After TAVR

June 12, 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

News Conference News SCAI 2019

Antithrombotic Use, Risk Perception, Varies Widely for PCI Patients With A-fib

Yael L. Maxwell

May 24, 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

News Conference News HRS 2019

Even in the DOAC Era, Women Less Likely Than Men to Receive Anticoagulation for A-fib

May 17, 2019

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

News Daily News

Younger Type 2 Diabetes Patients Face Higher Mortality and CVD Risks

Michael O'Riordan

April 10, 2019

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

News Daily News

Enlarged Left Atria Can ID Patients With ESUS Who May Benefit From a DOAC

April 08, 2019

Coping With CABANA: Despite Trial Flaws, A-fib Experts Say Lessons Have Been Learned

News Conference News EHRA 2019

Coping With CABANA: Despite Trial Flaws, A-fib Experts Say Lessons Have Been Learned

March 26, 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

News Conference News EHRA 2019

Edoxaban Joins Other NOACs as Option During Catheter Ablation for A-fib

March 21, 2019

Streamlined Procedure Maintains Benefits of Cryoablation Over Drugs for Paroxysmal A-fib

News Conference News EHRA 2019

Streamlined Procedure Maintains Benefits of Cryoablation Over Drugs for Paroxysmal A-fib

March 20, 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

News Conference News EHRA 2019

Survey Says . . . Patients Like NOACs Better Than Warfarin

March 17, 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

News Conference News ACC 2019

AUGUSTUS: Apixaban Plus P2Y12 Inhibitor the Best Combo in A-fib Patients With ACS or Undergoing PCI

March 17, 2019

Long-Awaited CABANA Publication Arrives, With Accompanying Quality-of-Life Study

News Daily News

Long-Awaited CABANA Publication Arrives, With Accompanying Quality-of-Life Study

March 15, 2019

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

News Daily News

DOACs in Patients With Mitral Stenosis and A-fib: Analysis Suggests a Benefit

March 12, 2019

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

News Daily News

High Rates of Unnecessary Aspirin Use in A-fib/VTE Patients on Warfarin

March 08, 2019

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

News Daily News

DOACs Maintain Advantage Over Warfarin in A-fib Patients With Low Body Weight

February 25, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

News Conference News ISC 2019

Off-Label Underdosing of DOACs Tied to Worse Outcomes in A-fib Patients

February 07, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

Stroke Risk Increases Over Time in Many Patients With A-fib

News Daily News

Stroke Risk Increases Over Time in Many Patients With A-fib

January 08, 2019

Quality of Anticoagulation Therapy Lower in Black Patients With A-fib

News Daily News

Quality of Anticoagulation Therapy Lower in Black Patients With A-fib

December 03, 2018

Complications Following TAVR Are Going Down, US Data Show

News Conference News AHA 2018

Complications Following TAVR Are Going Down, US Data Show

Yael L. Maxwell

November 20, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.